Center for the Neurobiology of Addiction Treatment

成瘾治疗神经生物学中心(CNAT)是维克森林大学健康科学中心的新版本，自1991年以来一直由NIDA资助。其具体目标是：1.为维克森林大学的NIDA研究人员之间提供一种新的互动机制，以检查可卡因药物疗法的神经生物学机制，使用紧密互动的项目以确保有效的协作结构；2.为我们的中心和我们在NIDA资助的两个临床中心的临床合作伙伴之间的协作互动提供一个正式的结构，从而为我们的研究提供一个新的翻译部分；3.为学生和博士后提供一个重点培训当代方法，以调查药物滥用的神经生物学基础；4.作为外行人和科学界与药物滥用的神经生物学方面相关问题的信息源。该中心的科学主题是研究目前用于或拟用于临床治疗可卡因成瘾的药物的神经生物学作用机制；这些研究将从托吡酯开始，并继续其他潜在的治疗药物，包括莫达非尼、D3多巴胺拮抗剂、食欲素拮抗剂等。中心将通过两个核心和三个重大项目的活动来实现这些目标。这些项目的设计是高度互动的，每个项目的活动取决于从其他两个项目获得的成果。项目1将检查药物治疗对大鼠和猴子各种行为模型的影响；项目2将通过神经成像和伏安法探索这些药物治疗范例如何影响大脑的功能结果；项目3将探索这些药物治疗如何影响从其他项目获得的脑组织中的基因和蛋白质表达、受体功能和信号转导系统。该中心的一个独特方面是与两个临床中心(宾夕法尼亚大学和弗吉尼亚大学)的密切互动，以提供翻译能力。行政核心将协调中心的活动，进行试点研究计划，并提供与临床中心的年度会议。组织核心中心将为这些项目提供统一的脑组织样本，供个别研究使用。这些项目利用了该中心研究人员在其资助历史的前几年独一无二地开发的几个动物模型和技术。

The Center for the Neurobiology of Addiction Treatment (CNAT) is a new version of a PSO Center at Wake Forest University Health Sciences that has been continuously funded by NIDA since 1991. The Specific Aims are: 1. to provide a novel mechanism of interaction between NIDA Investigators at Wake Forest University to examine neurobiological mechanisms of cocaine pharmacotherapies, using tightly interacting projects to ensure an effective collaborative structure; 2. to provide a formal structure of collaborative interactions between our Center and our clinical partners at two NIDA-funded clinical centers, thus providing a novel translational component to our research; 3. to provide a focus for the training of students and postdoctoral fellows in contemporary methods for investigating the neurobiological basis of drug abuse; 4. to serve as an information source to both the lay and scientific community on issues related to the neurobiological aspects of drug abuse. The scientific theme of the Center is focused on examining the neurobiological mechanisms of action of drugs that are currently used, or proposed for use in the clinic for treatment of cocaine addiction; these studies will begin with topiramate, and proceed with other potential treatment agents including modafinil, D3 dopamine antagonists, orexin antagonists, and others. The Center will accomplish these goals through the activities of two cores and three major projects. The projects are designed to be highly interactive, with each project's activities dependent on results obtained from the other two projects. Project 1 will examine effects of drug treatment on various behavioral models in both rats and monkeys; Project 2 will explore how these drug treatment paradigms affect functional consequences in brain through neuro-imaging and voltammetry; and Project 3 will explore how these drug treatments affect gene and protein expression, receptor function and signal transduction systems in brain tissue obtained from the other Projects. A unique aspect of the Center is the close interaction with two clinical Centers (at the University of Pennsylvania and the University of Virginia) to provide translational capabilities. The Administrative Core will coordinate Center activities, conduct a pilot studies program, and provide for annual meetings with clinical Centers. The Tissue Core will provide uniform sets of brain tissue samples to the projects for individual studies. These projects utilize several animal models and technologies uniquely developed by the Center investigators over the previous years of its funding history.